Global Information
회사소개 | 문의 | 위시리스트

자궁경부암 치료제 시장과 파이프라인 분석

Cervical Cancer Drug Market & Pipeline Insight

리서치사 PNS Pharma
발행일 2014년 06월 상품 코드 317352
페이지 정보 영문 165 Pages
US $ 1,800 ₩ 2,163,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스로 편집 및 인쇄가 불가능합니다.
US $ 2,100 ₩ 2,524,000 CD-ROM help
CD-ROM 의 형태로 우편 배송되며 편집 및 인쇄가 불가능합니다.
US $ 2,400 ₩ 2,884,000 Hard Copy help
Hard Copy의 형태로 우편 배송됩니다.
US $ 3,600 ₩ 4,327,000 PDF by E-mail (Multi-User License) help
동일 기업 내의 모든 직원들이 이용할 수 있는 라이선스입니다. 편집은 불가능하며 인쇄는 1회에 한해 가능합니다.

주의 : 본 보고서는 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.

자궁경부암 치료제 시장과 파이프라인 분석 Cervical Cancer Drug Market & Pipeline Insight
발행일 : 2014년 06월 페이지 정보 : 영문 165 Pages

자궁경부암은 세계 여성에게서 3번째로 발생 건수가 많고, 4번째로 사망 건수가 많은 암입니다. 조기 발견으로 최근 수년간 자궁경부암에 의한 사망률은 감소 경향을 나타냈지만, 과잉 진단 및 과잉 시술 등의 과제가 여전히 남아 있습니다. 세계 보건기구(WHO)에 의하면 매년 새롭게 50만명 이상이 자궁경부암으로 진단되어 매년 27만 5,000명 가까이가 사망하고 있습니다. 따라서 여전히 자궁경부암은 여러 암 중에서도 주요 건강 문제가 되고 있습니다.

자궁경부암(Cervical Cancer) 치료제 시장에 대해 조사했으며, 시장 개요, 단계·국가별 임상 분석, 출시된 치료제, 미개발 및 임상시험이 중지된 치료제의 개요, 경쟁 구도 등의 정보를 전해드립니다.

제1장 자궁경부암 치료제 시장 개요

  • 시장 개요
  • 임상 파이프라인 분석

제2장 자궁경부암 치료제 임상시험 분석, 단계별 및 국가별

  • 전임상
  • 임상
  • 단계 I
  • 단계 I/II
  • 단계 II
  • 단계 III

제3장 출시된 자궁경부암 치료제 임상 분석 및 특허 분석

제4장 중지 및 미개발 자궁경부암 치료제

  • 미개발
  • 중지

제5장 경쟁 구도

  • Advaxis
  • ApoVax
  • Genentech
  • GlaxoSmithKline
  • Inovio Pharmaceuticals
  • ISA Pharmaceuticals
  • Kaken Pharmaceutical
  • Merck


KSM 14.11.07

Cervical cancer is the third and fourth most common cause of cancer incidence and mortality among women across the world. Though there has been a decline in cervical cancer mortality rates in the previous few years, owing to early detection and intervention, challenges like over-diagnosis and over-treatment of the disease continue to remain. As per the World Health Organization (WHO), more than half a million new cases are diagnosed annually and there are close to 275,000 deaths every year. Thus, cervical cancer continues to be a major public health problem among the other cancers.

Significant amount of research is being undertaken to study the process of HPV infection causing precancerous changes in normal cells, which eventually leads to cervical cancer. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Once the results of these research activities are proved, there would be a major shift in the methods of treating this disease in the future.

Since there are no therapeutic vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. The current therapeutic vaccines have shown some systematic cellular immunity by intramuscular or subcutaneous injection. This has led the clinical trials to show cellular immune response to the vaccines. However, mucosal immunity at cervical mucosa is required and the pharma companies are currently focusing on this aspect. With the development of vaccines addressing this issue, there would be a significant reduction in the incidence rates of HPV across the globe.

Efforts are being made by the stakeholders to invest larger quantities of time and resources in obtaining a greater and deeper understanding of laboratory research which has indicated that HPVs (which are the major cause of cervical cancer), produce proteins which are called E5, E6, and E7. These proteins tend to interfere with the functions of the cells which normally prevent excessive growth. With a better knowledge of the mechanisms and working of these proteins, researchers could possibly be able to develop successful ways to limit the process by which HPV infection can lead to the growth of abnormal cells, thus controlling the incidence of cervical cancer.

"Cervical Cancer Drug Market & Pipeline Insight" Report Highlights:

  • Cervical Cancer Drug Market Overview
  • Marketed Drug Profiles & Patent Analysis
  • Clinical Trial Insight by Phase & Country
  • Drug in Clinical Development Phase: 47
  • Majority Drugs in Phase-II: 16
  • Marketed Cervical Cancer Drug: 6
  • Discontinued Drug Profiles: 26
  • Competitive Landscape

Table of Contents

1. Cervical Cancer Drug Market Overview

  • 1.1 Market Overview
  • 1.2 Clinical Pipeline Insight

2. Cervical Cancer Drug Clinical Trial Insight by Phase & Country

  • 2.1 Preclinical
  • 2.2 Clinical
  • 2.3 Phase I
  • 2.4 Phase I/II
  • 2.5 Phase II
  • 2.6 Phase III

3. Marketed Cervical Cancer Drug Clinical Insight & Patent Analysis

4. Discontinued & No Development Reported in Cervical Cancer Drug

  • 4.1 No Development Reported
  • 4.2 Discontinued

5. Competitive Landscape

  • 5.1 Advaxis
  • 5.2 ApoVax
  • 5.3 Genentech
  • 5.4 GlaxoSmithKline
  • 5.5 Inovio Pharmaceuticals
  • 5.6 ISA Pharmaceuticals
  • 5.7 Kaken Pharmaceutical
  • 5.8 Merck
  • Figure 1- 1: US - Number Cervical Cancer New Cases & Deaths, 2014
  • Figure 1- 2: Global Cervical Cancer Market (US$), 2013-2020
  • Figure 1- 3: Cervical Cancer Drugs in Pipeline by Phase (%), 2014
  • Figure 1- 4: Number of Cervical Cancer Drugs in Pipeline by Phase, 2014
  • Figure 1- 5: No Development in Cervical Cancer Drugs in Pipeline by Phase (%), 2014
  • Figure 1- 6: No Development in Cervical Cancer Drugs in Pipeline by Phase (Number), 2014
  • Figure 1- 7: Discontinued Cervical Cancer Drugs in Pipeline by Phase (%), 2014
  • Figure 1- 8: Number of Discontinued Cervical Cancer Drugs in Pipeline by Phase (%), 2014
  • Table 1-1: Europe - Cervical Cancer Estimated Incidence & Mortality by country, 2012

Following Information for Each Drug Profile is Covered in More than 200 Tables in Report:

  • Drug Profile Overview
  • Active Indication
  • Phase of Development
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class

List of Figures & Tables

Each Drug Profile has Tables Representing Following Information:

  • Alternate Names
  • Originator & Owner
  • Collaborator
  • Technology Provider
  • Licensee
  • Highest Development Phase
  • Indications
  • Class
  • Mechanism of Action
  • ATC Code
  • Designated Brand Name
Back to Top
전화 문의